Mechanism of Paraneoplastic Eosinophilia in Lymphoma
Paraneoplastic eosinophilia in lymphoma occurs through the production of eosinophilopoietic cytokines—particularly IL-5, IL-4, and IL-13—secreted by neoplastic lymphoma cells, which stimulate normal eosinophil precursors to proliferate and differentiate. 1
Primary Mechanism: Cytokine-Driven Reactive Eosinophilia
The eosinophilia in lymphoma is secondary (reactive), meaning the eosinophils themselves are not part of the malignant clone. Instead, the lymphoma cells act as a cytokine factory:
- T-cell lymphomas are particularly prone to causing eosinophilia because they produce Th2-type cytokines (IL-4, IL-5, IL-13) that directly stimulate eosinophil production 1
- IL-5 is the most critical cytokine, as it specifically drives eosinophil differentiation and proliferation 2, 3
- Hodgkin lymphoma and other B-cell and T-cell lymphomas frequently demonstrate this pattern 1
The mechanism has been directly demonstrated: immunostaining of lymphoma tissue shows lymphoma cells positive for IL-5, and when these patients respond to chemotherapy, both the lymphoma burden and eosinophil counts decrease in parallel, with normalization of serum IL-5 levels 2.
Lymphocyte-Variant Hypereosinophilic Syndrome (L-HES)
A specific subtype relevant to lymphoma is L-HES, which represents a hybrid condition:
- Characterized by clonal T-cells with aberrant immunophenotypes (CD3-/CD4+, CD3+/CD4-/CD8-, or CD3+/CD4+/CD7-) 1
- These abnormal T-cells secrete Th2 cytokines (IL-4, IL-5, IL-13) causing secondary reactive eosinophilia 1
- 10-20% of L-HES cases evolve into overt T-cell lymphoma or Sézary syndrome 1
- This is considered a "mixture" of clonal T-cell disease with secondary eosinophilia 1
Clinical Correlation
The eosinophil count typically correlates with lymphoma burden:
- Increases with disease progression and lymphadenopathy 4
- Decreases with effective chemotherapy 2, 4
- More frequent in T-cell lymphomas than B-cell lymphomas 1
- In advanced-stage solid tumors, similar cytokine-driven mechanisms apply 1
Key Distinction from Primary Eosinophilia
This is fundamentally different from primary (neoplastic) eosinophilia where:
- Eosinophils are part of the malignant clone (as in myeloid neoplasms with PDGFRA/PDGFRB/FGFR1 rearrangements)
- In lymphoma-associated eosinophilia, the eosinophils are normal cells responding to abnormal cytokine signals 1
Clinical Pitfall
Do not mistake marked eosinophilia for a primary eosinophilic disorder. When eosinophilia accompanies lymphoma, the eosinophils are reactive, not neoplastic. The treatment target is the lymphoma itself—treating the underlying malignancy will resolve the eosinophilia 2, 4. However, if eosinophilia persists despite lymphoma control, consider L-HES with potential for lymphoma evolution and perform T-cell immunophenotyping and TCR gene rearrangement studies 1.